AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster
Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)
Please Click the Link, AACR NCI EORTC 2019 Poster to Enlarge